Disclosure Of Entity's Operating Segments [Text Block]

Innate Pharma - Filing #2813423

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Disclosure of entity's operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	—	—	—	57 674 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	24 703 EUR
Tax expense (income)	—	—	—	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	— EUR
Profit (loss) before tax	—	—	—	57 972 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	45 478 EUR
Profit (loss) from continuing operations	—	—	—	57 972 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	45 478 EUR
Profit (loss)	—	— EUR	— EUR	58 103 EUR	— EUR	58 103 EUR	— EUR	— EUR	— EUR	—	— EUR	— EUR	— EUR	— EUR	52 809 EUR	— EUR	— EUR	52 809 EUR
Assets	207 863 EUR	—	—	—	—	—	—	—	—	267 496 EUR	—	—	—	—	—	—	—	—
Cash flows from (used in) operating activities	—	—	—	19 154 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	58 457 EUR
Cash flows from (used in) investing activities	—	—	—	1 877 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	917,000 EUR
Cash flows from (used in) financing activities	—	—	—	1 828 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	26 818 EUR
Disclosure of products and services [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]